What question did this study set out to answer?

The aim is to evaluate TRI-611, a molecular glue degrader targeting ALK in NSCLC with CNS metastases.

April 5, 2026

Abstract 4618: TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC including central nervous system metastases

Puntos clave

The aim is to evaluate TRI-611, a molecular glue degrader targeting ALK in NSCLC with CNS metastases.
Assessment of TRI-611's ability to bind ALK and CRBN to promote degradation.
Cellular proteomics profiling to determine selectivity across neosubstrates.
In vivo evaluation of TRI-611's effects on tumor regression in xenograft models.
TRI-611 demonstrated over 90% degradation of EML4-ALK within 1-2 hours.
The compound showed prolonged recovery half-life of more than 15 hours post-treatment.
Tri-611 was orally bioavailable and led to tumor regression in both subcutaneous and intracranial models.

Resumen

Abstract Therapeutic inhibition of Anaplastic Lymphoma Kinase (ALK) has transformed the treatment of ALK fusion-positive non-small cell lung carcinoma (NSCLC), but ALK tyrosine kinase inhibitors (TKIs) suffer from liabilities common to all orthosteric inhibitors, such as off-target kinase inhibition and resistance alleles in and around the TKI binding site. Molecular glue degraders (MGDs) that engage the CRL4CRBN E3 ligase to promote neosubstrate degradation offer an alternative therapeutic approach. Here we describe TRI-611, a potent, brain-penetrant MGD that promotes the proximity of ALK and CRBN via a unique, non-G loop degron interface that is distal from the kinase active site. TRI-611 functions by engaging CRBN to create a neosurface that interacts with the C-lobe of the ALK kinase domain. This ALK:TRI-611:CRBN ternary complex promotes ALK polyubiquitination and CRBN-dependent degradation of ALK proteins, including ALK fusions such as EML4-ALK, and oncogenic, transmembrane ALK. Cellular degradation of EML4-ALK is rapid (occurring within 1-2 hours), robust (90% maximum degradation), and durable (recovery half-life of more than 15 hours after compound withdrawal). Cellular proteomics profiling demonstrates the profound selectivity of TRI-611 across CRBN neosubstrates and the kinome (including key off-target kinase families such as NTRK), consistent with the unique degron interface located in a less conserved region of ALK. TRI-611 treatment leads to inhibition of downstream signaling and subsequent selective anti-proliferation of ALK-positive cell lines. TRI-611 is orally bioavailable and brain penetrant, with daily oral dosing leading to deep and durable degradation of endogenous EML4-ALK and tumor regression in both subcutaneous and intracranial xenograft models of ALK-positive NSCLC. TRI-611 represents the first example of a development stage degrader targeting an oncogenic gene fusion and has the potential to expand the arsenal of meaningful therapeutic options for ALK-positive NSCLC patients. The discovery of TRI-611 additionally broadens the reach of CRBN-modulating MGDs by exploiting a previously undescribed degron. Citation Format: Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella, . TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC including central nervous system metastases abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4618.

Me gusta

Guardar